AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NEUROTECH INTERNATIONAL LTD

0.011

+0.00110.00%

Volume:266.64K

Turnover:2.93K

Market Cap:14.26M

PE:-2.92

High:0.011

Open:0.011

Low:0.011

Close:0.010

52wk High:0.037

52wk Low:0.010

Shares:1.30B

Float Shares:768.08M

Volume Ratio:0.86

T/O Rate:0.03%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.004

EPS(LYR):-0.010

ROE:-66.30%

ROA:-37.64%

PB:2.43

PE(LYR):-1.08

Loading ...

Overview Company News Filings

BUZZ-Australia's Neurotech International slips most since April on discounted placement

BRIEF-Neurotech International Receives A$4 Million Placement Commitments

Neurotech International Ltd - Receives a$4 Mln Placement Commitments

THOMSON REUTERS

BRIEF-Neurotech International Requests Trading Halt Pending Capital Raising Announcement

Neurotech International Ltd-Neurotech Receives $4.73M R&D Tax Incentive Refund

THOMSON REUTERS

BUZZ-Australia's Neurotech International jumps as US FDA grants rare disease status for drug candidate

Neurotech International Secures FDA Rare Pediatric Disease Designation for Rett Syndrome Drug

MT Newswires Live

Neurotech International - US FDA Rare Pediatric Disease Designation for Nti164 in Rett Syndrome

THOMSON REUTERS

Neurotech Starts Authorized Prescriber Program for Autism Therapy Candidate, Shares Up 6%

MT Newswires Live

ASX Biggest Losers

MT Newswires Live

BRIEF-Neurotech International Posts FY Loss Attributable A$10.6 Million

Change of Registered Address & Principal Place of Business-NTI.AX

Becoming a substantial holder-NTI.AX

New Scientific Publication of Phase I/II Rett Syndrome Trial-NTI.AX

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NTI.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NTI.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NTI.AU\",,,,,undefined,":{"symbol":"NTI.AU","market":"AU","secType":"STK","nameCN":"NEUROTECH INTERNATIONAL LTD","latestPrice":0.011,"timestamp":1774228935218,"preClose":0.01,"halted":0,"volume":266637,"delay":0,"changeRate":0.09999999999999991,"nameEN":"NEUROTECH INTERNATIONAL LTD","floatShares":768083617,"shares":1296313116,"eps":-0.003762,"marketStatus":"Trading","change":0.001,"latestTime":"03-23 12:37:42 AEDT","open":0.011,"high":0.011,"low":0.011,"amount":2933,"amplitude":0,"askPrice":0.011,"askSize":263394,"bidPrice":0.01,"bidSize":4114320,"shortable":3,"etf":0,"ttmEps":-0.003762,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1774242000000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.01,"openAndCloseTimeList":[[1774220400000,1774242000000]],"volumeRatio":0.857451,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"NTI.AU","preClose":0.011,"auctionPrice":0.011,"auctionVolume":945,"auction":3,"marketStatus":"盘后竞价","timestamp":1773982812707}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NTI.AU\",,,,,undefined,":{"symbol":"NTI.AU","floatShares":768083617,"roa":"-37.64%","roe":"-66.30%","lyrEps":-0.010231,"volumeRatio":0.857451,"shares":1296313116,"dividePrice":0,"high":0.011,"amplitude":0,"preClose":0.01,"low":0.011,"week52Low":0.01,"pbRate":"2.43","psRate":"2.02","week52High":0.037,"institutionHeld":0,"latestPrice":0.011,"committee":0.879666,"eps":-0.003762,"divideRate":0,"volume":266637,"delay":0,"ttmEps":-0.003762,"open":0.011,"prevYearClose":0.014,"prevWeekClose":0.01,"prevMonthClose":0.013,"prevQuarterClose":0.014,"fiveDayClose":0.011,"twentyDayClose":0.013,"sixtyDayClose":0.016,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NTI.AU\",params:#limit:5,,,undefined,":[{"date":"2023-10-27","symbol":"NTI.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1698361200000,"name":null,"time":"","dateTimestamp":1698325200000,"actualEps":null},{"date":"2023-07-26","symbol":"NTI.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1690329600000,"name":null,"time":"","dateTimestamp":1690293600000,"actualEps":null},{"market":"AU","date":"2023-04-27","symbol":"NTI.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1682517600000,"reportTimeType":"","actualEps":null},{"date":"2023-01-30","symbol":"NTI.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1675033200000,"name":null,"time":"","dateTimestamp":1674997200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NTI.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NTI.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2592303957","title":"BUZZ-Australia's Neurotech International slips most since April on discounted placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2592303957","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592303957?lang=en_us&edition=fundamental","pubTime":"2025-12-17 10:34","pubTimestamp":1765938853,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neurotech International slips most since April on discounted placement** Neurotech International NTI.AX slips as much as 18.9% to A$0.015; marks biggest intraday pct decline since April 4** Stock hits lowest since September 22** Biopharmaceutical co announces A$4 million  placement at A$0.014/share** Issue price represents 26.3% discount to last close** Funds raised will be applied towards registration-enabling clinical programmes, others** Nearly 2 million shares traded, 4.1x the 30-day average** YTD, NTI down 72.7%  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nL4N3XN070:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7007","NTI.AU"],"gpt_icon":0},{"id":"2592548419","title":"BRIEF-Neurotech International Receives A$4 Million Placement Commitments","url":"https://stock-news.laohu8.com/highlight/detail?id=2592548419","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592548419?lang=en_us&edition=fundamental","pubTime":"2025-12-17 09:25","pubTimestamp":1765934717,"startTime":"0","endTime":"0","summary":"BRIEF-Neurotech International Receives A$4 Million Placement CommitmentsDec 17 (Reuters) - Neurotech International Ltd NTI.AX:RECEIVES A$4 MILLION PLACEMENT COMMITMENTSFurther company coverage: NTI.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nFWN3XM106:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7007","NTI.AU"],"gpt_icon":0},{"id":"2592531059","title":"Neurotech International Ltd - Receives a$4 Mln Placement Commitments","url":"https://stock-news.laohu8.com/highlight/detail?id=2592531059","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592531059?lang=en_us&edition=fundamental","pubTime":"2025-12-17 07:02","pubTimestamp":1765926162,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nFWN3XM106:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NTI.AU","BK7007"],"gpt_icon":0},{"id":"2591678196","title":"BRIEF-Neurotech International  Requests Trading Halt Pending Capital Raising Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2591678196","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591678196?lang=en_us&edition=fundamental","pubTime":"2025-12-15 06:22","pubTimestamp":1765750977,"startTime":"0","endTime":"0","summary":"BRIEF-Neurotech International  Requests Trading Halt Pending Capital Raising AnnouncementDec 15 (Reuters) - Neurotech International Ltd NTI.AX:REQUESTS TRADING HALT PENDING CAPITAL RAISING ANNOUNCEMENTFurther company coverage: NTI.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251214:nFWN3XI0RP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTI.AU","BK7007"],"gpt_icon":0},{"id":"2582231312","title":"Neurotech International Ltd-Neurotech Receives $4.73M R&D Tax Incentive Refund","url":"https://stock-news.laohu8.com/highlight/detail?id=2582231312","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582231312?lang=en_us&edition=fundamental","pubTime":"2025-11-12 06:53","pubTimestamp":1762901593,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nTUE1GP6NW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NTI.AU","BK7007"],"gpt_icon":0},{"id":"2573997262","title":"BUZZ-Australia's Neurotech International jumps as US FDA grants rare disease status for drug candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2573997262","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573997262?lang=en_us&edition=fundamental","pubTime":"2025-10-08 08:33","pubTimestamp":1759883626,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neurotech International jumps as US FDA grants rare disease status for drug candidate** Shares of Australia's Neurotech International NTI.AX rise as much as 52.6% to A$0.029, their biggest intraday pct gain since early-July 2020** Stock at its highest level since April 23** NTI stock up 10.5% currently** Biopharmaceutical co says U.S. FDA granted rare pediatric disease designation for drug candidate, NTI164, for treatment of Rett syndrome** Rett syndrome is a rare genetic neurological and developmental disorder that affects ways in which brain develops** Nearly 15.3 million shares change hands, 13.2x the 30-day average volume ** Stock has fallen 61.8% this year, as 0024 GMT  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nL3N3VP00F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7007","NTI.AU"],"gpt_icon":0},{"id":"2573992281","title":"Neurotech International Secures FDA Rare Pediatric Disease Designation for Rett Syndrome Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2573992281","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573992281?lang=en_us&edition=fundamental","pubTime":"2025-10-08 07:59","pubTimestamp":1759881584,"startTime":"0","endTime":"0","summary":"Neurotech International  has received a rare pediatric disease designation from the US Food and Drug Administration  for its lead drug candidate, NTI164, for the treatment of Rett syndrome, according to a Wednesday filing with the Australian bourse.This milestone adds to NTI164's previously granted orphan drug designation, strengthening the company's position in developing therapies for rare neurological disorders, the filing said.The FDA's decision was based on Rett syndrome being a serious, life-threatening, and rare condition, the filing added.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7007","NTI.AU"],"gpt_icon":0},{"id":"2573919319","title":"Neurotech International - US FDA Rare Pediatric Disease Designation for Nti164 in Rett Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2573919319","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573919319?lang=en_us&edition=fundamental","pubTime":"2025-10-08 06:24","pubTimestamp":1759875873,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nFWN3VO2N4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7007","NTI.AU"],"gpt_icon":0},{"id":"2569765216","title":"Neurotech Starts Authorized Prescriber Program for Autism Therapy Candidate, Shares Up 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2569765216","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569765216?lang=en_us&edition=fundamental","pubTime":"2025-09-23 12:29","pubTimestamp":1758601777,"startTime":"0","endTime":"0","summary":"Neurotech International  opened an authorized prescriber program for its therapy candidate NTI164, across a range of neurodevelopmental conditions for paediatric patients in Australia, according to a Tuesday Australian bourse filing.The program aims to generate real-world clinical data to complement the ongoing and planned clinical and registration trials, and the data will provide further evidence of safety and efficacy across a broader patient population and strengthen regulatory submissions, advocacy efforts, and partnering discussions.The launch of the program follows recent changes to the National Disability Insurance Scheme, which will see children with mild to moderate autism spectrum disorder diverted off the NDIS and into a newly established program by mid-2027.The company's shares rose 6% in recent Tuesday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NTI.AU","XKO.AU","BK7007","XJO.AU","XAO.AU"],"gpt_icon":0},{"id":"2566944893","title":"ASX Biggest Losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2566944893","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566944893?lang=en_us&edition=fundamental","pubTime":"2025-09-12 11:01","pubTimestamp":1757646095,"startTime":"0","endTime":"0","summary":"Here are the 10 ASX-listed companies with the biggest losses on Friday.DOTZ Nano : -23%, AU$0.046Kaili Resources : -22%, AU$0.26Neurotech International : -16%, AU$0.016Atomos : -15%, AU$0.011Desoto Resources : -14%, AU$0.18Element 25 : -13%, AU$0.29Noble Helium : -13%, AU$0.042Jindalee Lithium : -11%, AU$0.53Resources & Energy Group : -10%, AU$0.026Hawk Resources : -10%, AU$0.019","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["KLR.AU","BK7095","BK7083","HWK.AU","AMS.AU","BK7142","E25.AU","DTZ.AU","REZ.AU","DES.AU","JLL.AU","BK7076","BK7104","BK7003","NTI.AU","NHE.AU","BK7007"],"gpt_icon":1},{"id":"2563801239","title":"BRIEF-Neurotech International Posts FY Loss Attributable A$10.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2563801239","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563801239?lang=en_us&edition=fundamental","pubTime":"2025-08-29 16:13","pubTimestamp":1756455208,"startTime":"0","endTime":"0","summary":"BRIEF-Neurotech International Posts FY Loss Attributable A$10.6 MillionAug 29 (Reuters) - Neurotech International Ltd NTI.AX:FY LOSS ATTRIBUTABLE A$10.6 MILLIONFY REVENUES FROM ORDINARY ACTIVITIES A$2.6 MILLIONFurther company coverage: NTI.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nFWN3UK1T0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7007","NTI.AU"],"gpt_icon":0},{"id":"2550161384","title":"Change of Registered Address & Principal Place of Business-NTI.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2550161384","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550161384?lang=en_us&edition=fundamental","pubTime":"2025-07-10 14:32","pubTimestamp":1752129131,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250710:nASX71MgMh","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250710:nASX23NyrZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTI.AU","BK7007"],"gpt_icon":0},{"id":"2550395680","title":"Becoming a substantial holder-NTI.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2550395680","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550395680?lang=en_us&edition=fundamental","pubTime":"2025-07-09 16:58","pubTimestamp":1752051499,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250709:nASX1qPhhV","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250709:nASX8XQrlp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTI.AU","BK7007"],"gpt_icon":0},{"id":"2549374940","title":"New Scientific Publication of Phase I/II Rett Syndrome Trial-NTI.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2549374940","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549374940?lang=en_us&edition=fundamental","pubTime":"2025-07-07 07:32","pubTimestamp":1751844770,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250706:nASX6nswVk","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250706:nASXbPQzyN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTI.AU","BK7007"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":14,"code":"91000000","status":"200"}]}}